ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 110

Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases

Janna Shapiro1, Florence Choi2, Amy Xu3, Trang Duong4, Tania Watts1, Anne-Claude Gingras5, Sasha Bernatsky6, Susanne Benseler7 and Rae Yeung8, 1Department of Immunology, University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 3The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, 4Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, 5Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, 6Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 7Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, 8The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Biologicals, COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards), Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, March 31, 2023

Title: Posters: Clinical and Therapeutic II

Session Type: Poster Session B

Session Time: 5:00PM-6:00PM

Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressants

Methods: A prospective observational study was conducted at Canadian paediatric centers. Children under the age of 18 with autoimmune disease (rheumatic and/or inflammatory bowel disease) were eligible for the study regardless of treatment. Antibodies against SARS-CoV-2 spike and receptor-binding domain were measured in either serum or dried blood spots collected after each COVID-19 vaccine dose. The kinetics and magnitude of antibody response following each vaccine dose were compared between treatment groups, using mixed-effects multivariable regression models. Participants who had been diagnosed with COVID-19 were excluded from the current analysis.

Results: From clinical and research registries, 2199 potential subjects were identified and 1941 were contacted by letter and telephone or during a clinic visit. From these, 239 individuals consented to participate in the study. For the current analyses, 116 participants contributed 57 samples post-COVID-19 vaccination dose 2, 59 samples post-dose 3, and 22 samples post-dose 4. It was found that anti-spike IgG responses were both reduced in magnitude and waned faster for participants treated with biologic DMARDs (disease modifying anti-rheumatic drugs) than for those who were treatment naive or receiving traditional DMARD therapy post-dose 2. For post-dose 3, IgG responses remained lower in the biologics group, but there were no clear differences in waning over time. After dose 4, no differences between the groups were observed. Among the biologics, anti-TNF therapies and rituximab had the greatest effect on IgG titers.

Conclusion: Antibody responses to COVID-19 vaccination in children with autoimmune diseases was lowest in individuals treated with biologics, particularly with anti-TNF agents and rituximab. Third and fourth vaccine doses are necessary to yield robust and durable antibody responses.


Disclosures: J. Shapiro: None; F. Choi: None; A. Xu: None; T. Duong: None; T. Watts: None; A. Gingras: None; S. Bernatsky: None; S. Benseler: None; R. Yeung: None.

To cite this abstract in AMA style:

Shapiro J, Choi F, Xu A, Duong T, Watts T, Gingras A, Bernatsky S, Benseler S, Yeung R. Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/medications-affect-antibody-responses-to-covid-19-vaccinations-in-children-with-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medications-affect-antibody-responses-to-covid-19-vaccinations-in-children-with-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology